Indian Journal of Pharmacology Home 

LETTER TO THE EDITOR
[Download PDF]
Year : 2011  |  Volume : 43  |  Issue : 3  |  Page : 360--361

Authors' reply

Pramod B Akat, Tushar R Bapat, Mangala B Murthy, Vitthal B Karande, Shreyas R Burute 
 Department of Pharmacology, Government Medical College, Miraj, Maharashtra, India

Correspondence Address:
Pramod B Akat
Department of Pharmacology, Government Medical College, Miraj, Maharashtra
India




How to cite this article:
Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR. Authors' reply.Indian J Pharmacol 2011;43:360-361


How to cite this URL:
Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR. Authors' reply. Indian J Pharmacol [serial online] 2011 [cited 2020 Feb 25 ];43:360-361
Available from: http://www.ijp-online.com/text.asp?2011/43/3/360/81490


Full Text

Sir,

We thank for the valuable comments [1] on our paper. [2] Our reply to the queries is as follows:

Sample size in our study was calculated by using the formula [3] for sample size estimation for quantitative data and was found adequate. The results of previous study were used for calculations. The power of our study was 90% at 1% level of significance.We regret the typing error. Please read the range as mild hypertension systolic blood pressure (SBP)/diastolic blood pressure (DBP): 140-159/90-99 mmHg. Moderate hypertension SBP/DBP: 160-179/100-109 mmHg.Suggestion at 3 is well taken for future studies.It is clear from the background of our study that the study was planned to focus on advantages of telmisartan over enalapril. Taking this into consideration, the diastolic BP was taken as primary end point and systolic BP was measured simultaneously; therefore, its relevance in the study remains clear. There is strong evidence that systolic BP is a better predictor of cardiovascular events in persons older than 50 years, but diastolic BP is still considered as a better predictor of cardiovascular events than systolic BP [4] in young hypertensives. Therefore, to evaluate the efficacy, telmisartan was compared with enalapril, taking diastolic BP as the primary end point.

References

1Saha L. Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension. Indian J Pharmacol 2011;43:360.
2Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR. Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension. Indian J Pharmacol 2010;42:153-6.
3Kadam P, Bhalerao S. Sample size calculation. Int J Ayurveda Res 2010;1:55-7.
4Perry HM Jr, Miller JP, Baty JD, Carmody SE, Sambhi MP. Pretreatment blood pressure as a predictor of 21-year mortality. Am J Hypertens 2000;13:724-33.